Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.71 |
| ▸ | MLYCD | O95822 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495709 | 0.90 | KMT2A (0.69) | KMT2AMEN1HDAC1HDAC6MLYCD | |
| SCHEMBL2921609 | 0.89 | KMT2A (0.68) | KMT2AMEN1HDAC1HDAC6MLYCD | |
| SCHEMBL3455399 | 0.89 | LIMK2 (0.69) | KMT2AMEN1HDAC1HDAC6MLYCD | |
| SCHEMBL2118597 | 0.88 | KMT2A (0.66) | KMT2AMEN1HDAC1HDAC6MLYCD | |
| SCHEMBL5644792 | 0.88 | LIMK2 (0.70) | KMT2AMEN1HDAC1HDAC6MLYCD | |
| SCHEMBL4937857 | 0.88 | HDAC1 (0.66) | KMT2AMEN1HDAC1HDAC6MLYCD | |
| SCHEMBL19630546 | 0.88 | KMT2A (0.66) | KMT2AMEN1HDAC1HDAC6MLYCD | |
| SCHEMBL5645455 | 0.88 | NSD2 (0.67) | KMT2AMEN1HDAC1HDAC6MLYCD | |
| SCHEMBL11187328 | 0.88 | KMT2A (0.66) | KMT2AMEN1HDAC1HDAC6MLYCD | |
| SCHEMBL5643137 | 0.88 | HDAC1 (0.66) | KMT2AMEN1HDAC1HDAC6MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912647-B2 | Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912647-B2 | Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912647-B2 | Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-110803995-B | Method for synthesizing tertiary amine derivative through hydroboration reaction of tertiary amide under catalysis of rare earth | 温州医科大学 | 2022-07-08 | — | — | CN | disclosed |
| US-20210363098-A1 | DIVERSITY-ORIENTED SYNTHESIS OF N,N,O-TRISUBSTITUTED HYDROXYLAMINES FROM ALCOHOLS AND AMINES BY N-O BOND FORMATION | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2021-11-25 | — | — | US | disclosed |
| US-20210363098-A1 | DIVERSITY-ORIENTED SYNTHESIS OF N,N,O-TRISUBSTITUTED HYDROXYLAMINES FROM ALCOHOLS AND AMINES BY N-O BOND FORMATION | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2021-11-25 | — | — | US | disclosed |
| CN-110803995-A | Method for synthesizing tertiary amine derivative by hydroboration reaction of tertiary amide under catalysis of rare earth | 温州医科大学 | 2020-02-18 | — | — | CN | disclosed |
| CN-107151226-B | A kind of preparation method of polysubstituted isoindolinone | 中国科学院化学研究所 | 2019-08-23 | — | — | CN | disclosed |
| CN-109180518-A | Secondary/teritary amide class the compound of one kind and its synthetic method | 陕西科技大学 | 2019-01-11 | — | — | CN | disclosed |
| US-8778219-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| EP-1862181-A2 | Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-12-05 | — | — | EP | disclosed |
| EP-1854487-A2 | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007122173-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | disclosed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | disclosed |
| US-20060100235-A1 | Pharmaceutical use of substituted 1,2,4-triazoles | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | US | disclosed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | disclosed |
| EP-0613879-A1 | PHELLODENDRINE ANALOGS AND ALLERGY TYPE IV SUPPRESSOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1994-09-07 | — | — | EP | disclosed |
| US-4000159-A | PREPARATION OF N,N-DISUBSTITUTED THIOAMIDES | PHILLIPS PETROLEUM COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363098-A1 | DIVERSITY-ORIENTED SYNTHESIS OF N,N,O-TRISUBSTITUTED HYDROXYLAMINES FROM ALCOHOLS AND AMINES BY N-O BOND FORMATION | ADH5, ADH1A, NAT1 | KMT2A 1702/4885MEN1 3283/4885HDAC1 1483/4885 |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | KMT2A 3419/4885MEN1 2970/4885HDAC1 516/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | KMT2A 3018/4885MEN1 1615/4885HDAC1 304/4885 |
| US-11912647-B2 | Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation | ADH5, ADH1A, NAT1 | KMT2A 1627/4885MEN1 3153/4885HDAC1 1403/4885 |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | KMT2A 3134/4885MEN1 2380/4885HDAC1 114/4885 |
| US-20060100235-A1 | Pharmaceutical use of substituted 1,2,4-triazoles | HSD3B1, HSD11B1, HSD3B2 | KMT2A 3816/4885MEN1 1800/4885HDAC1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.